This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Tandem, Tandem Plus
- Generic Name
- Iron polymaltose
- DrugBank Accession Number
- DB15763
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Iron polymaltose (DB15763)
- Weight
- Average: 449.163
Monoisotopic: 449.059366 - Chemical Formula
- C12H25FeO14
- Synonyms
- Ferric hydroxide polymaltose complex
- Ferromaltose
- Iron polymaltose
- Iron polymaltose complex
- Iron(III)-hydroxide polymaltose complex
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to prevent Folate deficiency Combination Product in combination with: Folic acid (DB00158) •••••••••••• ••••••••••••• ••••• Used in combination to treat Folate deficiency Combination Product in combination with: Folic acid (DB00158) •••••••••••• ••••••••••••• ••••• Used in combination to treat Folate deficiency Combination Product in combination with: Folic acid (DB00158) •••••••••••• ••••••••• ••••• Used in combination to prevent Folate deficiency Combination Product in combination with: Folic acid (DB00158) •••••••••••• ••••••••• ••••• Used in combination to treat Iron deficiency Combination Product in combination with: Folic acid (DB00158) •••••••••••• ••••••••••••• ••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlendronic acid Iron polymaltose can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Almasilate Almasilate can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminium phosphate Aluminium phosphate can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy. Asenapine Asenapine can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Amylofer / Ferinject / Ferripel 3 / Ferripel-3 / Injectafer / Maltofer / Teferrol
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image EUROFER® -iron syrup Syrup 1 g/100ml Oral EURODRUG LABORATORIES (M) SDN BHD 2020-09-08 Not applicable Malaysia 
MALTOFER Syrup 50 mg/5ml Oral บริษัท ดีเคเอสเอช (ประเทศไทย) จำกัด 2009-04-23 Not applicable Thailand 
MALTOFER FILM-COATED TABLETS 100MG Tablet, film coated 100 mg Oral VIFOR PHARMA ASIA PACIFIC PTE. LTD. 2016-06-04 Not applicable Singapore 
MALTOFER SYRUP 50mg/5ml Syrup 10 mg/ml Oral VIFOR PHARMA ASIA PACIFIC PTE. LTD. 1991-08-04 Not applicable Singapore Saferon Drops 50mg/ml Solution / drops Oral Glenmark Pharmaceuticals (Malaysia) Sdn. Bhd. 2020-09-08 Not applicable Malaysia - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image CHALVER HEMATIN FOL® Iron polymaltose (1 g) + Folic acid (4000 mcg) Syrup Oral LABORATORIOS CHALVER DE COLOMBIA S.A.S. 2006-11-10 Not applicable Colombia 
HEMATIN PLUS JARABE Iron polymaltose (1 g) + Nicotinamide (0.5 g) + Pyridoxine (50 mg) + Riboflavin sodium (50 mg) + Thiamine hydrochloride (50 mg) Syrup Oral LABORATORIOS CHALVER DE COLOMBIA S.A. 2006-11-10 Not applicable Colombia HERREX FOL® JARABE Iron polymaltose (1 g) + Folic acid (2.4 mg) Syrup Oral ALTEA FARMACEUTICA S.A. 2006-11-10 Not applicable Colombia HERREX® FOL 1000 TABLETAS RECUBIERTAS Iron polymaltose (100 mg) + Folic acid (1 mg) Tablet, coated Oral ALTEA FARMACEUTICA S.A. 2007-10-03 Not applicable Colombia IROFAS Syrup Iron polymaltose (50 mg/5ml) + Ascorbic acid (100 mg/5ml) + Folic acid (2 mg/5ml) Syrup Oral HEALOL PHARMACEUTICALS SDN. BHD. 2020-09-08 Not applicable Malaysia
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- UM5219H89V
- CAS number
- 53858-86-9
- InChI Key
- PKMVWNYIYVZXIQ-MPAYLTKRSA-K
- InChI
- InChI=1S/C12H22O11.Fe.3H2O/c13-1-4(15)7(17)8(18)5(16)3-22-12-11(21)10(20)9(19)6(2-14)23-12;;;;/h1,4-12,14-21H,2-3H2;;3*1H2/q;+3;;;/p-3/t4-,5+,6+,7+,8+,9+,10-,11+,12-;;;;/m0..../s1
- IUPAC Name
- iron(3+) (2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexanal trihydroxide
- SMILES
- [OH-].[OH-].[OH-].[Fe+3].OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]1O
References
- General References
- Not Available
- External Links
- ChemSpider
- 32701213
- 37744
- Wikipedia
- Iron_polymaltose
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Endothelial Dysfunction / Iron Toxicity / Renal Anemia / Stress Oxidative 1 4 Completed Treatment Anemia / Colorectal Neoplasms 1 4 Completed Treatment Anemia / Gastrointestinal Hemorrhage 1 4 Completed Treatment Anemia / Heart Failure / Iron Deficiency (ID) 1 4 Completed Treatment Anemia / Iron Deficiency (ID) 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Oral Solution Intramuscular 100.000 mg Syrup Oral 1 g/100ml Solution Oral 100 mg/5ml Syrup Oral 50 mg/5ml Tablet, film coated Oral 101 mg Solution Intravenous 500 mg/10ml Solution Oral 64516 mg/ml Solution Oral 64517 mg/ml Solution / drops Oral 50 mg/ml Injection, solution Intramuscular 100 mg/2ml Granule, effervescent Oral 100 mg Granule, effervescent Oral 40 mg Injection, solution Intramuscular 10 mg/2ml Capsule Oral Powder Oral Syrup Oral 1 g Solution Oral 50 mg Tablet, coated Oral Solution Intravenous 100 mg/2ml Injection, solution Intramuscular 317 mg/2ml Syrup Oral Tablet, film coated Oral 100 mg Tablet, chewable Oral Syrup Oral 10 mg/ml Injection, solution Intramuscular Capsule Syrup Oral Injection Intramuscular 100 mg/2ml Syrup Oral 50 mg/1ml Solution / drops Oral Syrup Oral 200 mg/5mL Tablet, film coated Oral Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 229.0 mg/mL ALOGPS logP -2.8 ALOGPS logP -5.3 Chemaxon logS -0.17 ALOGPS pKa (Strongest Acidic) 11.93 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 11 Chemaxon Hydrogen Donor Count 8 Chemaxon Polar Surface Area 197.37 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 69.76 m3·mol-1 Chemaxon Polarizability 31.4 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at August 19, 2020 22:26 / Updated at August 21, 2020 19:35